DE69232460T2 - Die ansteckung blockierende malariaimpfstoffe - Google Patents
Die ansteckung blockierende malariaimpfstoffeInfo
- Publication number
- DE69232460T2 DE69232460T2 DE69232460T DE69232460T DE69232460T2 DE 69232460 T2 DE69232460 T2 DE 69232460T2 DE 69232460 T DE69232460 T DE 69232460T DE 69232460 T DE69232460 T DE 69232460T DE 69232460 T2 DE69232460 T2 DE 69232460T2
- Authority
- DE
- Germany
- Prior art keywords
- present
- vaccines
- malaria vaccine
- transmission
- pfs25
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000000903 blocking effect Effects 0.000 title 1
- 230000002458 infectious effect Effects 0.000 title 1
- 229940124735 malaria vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 210000005253 yeast cell Anatomy 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/70—Vector systems having a special element relevant for transcription from fungi
- C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/697,275 US5217898A (en) | 1988-05-02 | 1991-05-08 | Expression of the P. falciparum transmission-blocking antigen in yeast |
PCT/US1992/003579 WO1992019758A1 (en) | 1991-05-08 | 1992-05-07 | Transmission-blocking vaccine against malaria |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69232460D1 DE69232460D1 (de) | 2002-04-11 |
DE69232460T2 true DE69232460T2 (de) | 2002-09-26 |
Family
ID=24800510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69232460T Expired - Fee Related DE69232460T2 (de) | 1991-05-08 | 1992-05-07 | Die ansteckung blockierende malariaimpfstoffe |
Country Status (6)
Country | Link |
---|---|
US (1) | US5217898A (de) |
EP (1) | EP0584201B1 (de) |
AT (1) | ATE214097T1 (de) |
AU (1) | AU662151B2 (de) |
DE (1) | DE69232460T2 (de) |
WO (1) | WO1992019758A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014486A1 (en) | 1991-02-22 | 1992-09-03 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE | Transmission blocking vaccine against malaria |
US6355256B1 (en) | 1994-09-30 | 2002-03-12 | Ludwig Institute For Cancer Research | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof |
GB9422827D0 (en) * | 1994-11-11 | 1995-01-04 | Imperial College | Delivery system |
US5858378A (en) * | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
US6136794A (en) * | 1998-02-02 | 2000-10-24 | Merck & Co., Inc. | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
US6841155B1 (en) * | 1998-04-30 | 2005-01-11 | Chiron S.R.L. | Immunization against and treatment for infection by H. pylori |
ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
CN102838668A (zh) * | 2012-09-13 | 2012-12-26 | 兰州生物制品研究所有限责任公司 | 一种恶性疟原虫pfs25蛋白二聚体衍生物及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4546082A (en) * | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
US4735799A (en) * | 1987-01-14 | 1988-04-05 | Patarroyo Manuel E | Malaria vaccine |
JP2812759B2 (ja) * | 1988-05-02 | 1998-10-22 | アメリカ合衆国 | ヒトマラリアワクチン抗原をコードする遺伝子 |
WO1992014486A1 (en) * | 1991-02-22 | 1992-09-03 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE | Transmission blocking vaccine against malaria |
AU674491B2 (en) * | 1991-03-20 | 1997-01-02 | Virogenetics Corporation | Recombinant poxvirus malaria vaccine |
-
1991
- 1991-05-08 US US07/697,275 patent/US5217898A/en not_active Expired - Lifetime
-
1992
- 1992-05-07 WO PCT/US1992/003579 patent/WO1992019758A1/en active IP Right Grant
- 1992-05-07 AU AU19132/92A patent/AU662151B2/en not_active Expired
- 1992-05-07 EP EP92911372A patent/EP0584201B1/de not_active Expired - Lifetime
- 1992-05-07 DE DE69232460T patent/DE69232460T2/de not_active Expired - Fee Related
- 1992-05-07 AT AT92911372T patent/ATE214097T1/de active
Also Published As
Publication number | Publication date |
---|---|
ATE214097T1 (de) | 2002-03-15 |
EP0584201A1 (de) | 1994-03-02 |
EP0584201A4 (en) | 1997-03-19 |
AU662151B2 (en) | 1995-08-24 |
DE69232460D1 (de) | 2002-04-11 |
AU1913292A (en) | 1992-12-21 |
EP0584201B1 (de) | 2002-03-06 |
US5217898A (en) | 1993-06-08 |
WO1992019758A1 (en) | 1992-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69228698D1 (de) | HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG | |
DE69431665T2 (de) | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus | |
EP1964573A3 (de) | Verfahren zur Induzierung und/oder Verbesserung einer Immunreaktion auf Tumorantigene | |
ATE359089T1 (de) | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus | |
DE69232460T2 (de) | Die ansteckung blockierende malariaimpfstoffe | |
ATE320444T1 (de) | Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren | |
WO1995026982A3 (en) | Malaria peptides | |
DE69031426T2 (de) | Impfstoff zur immunisierung von katzen gegen toxoplasmen ohne verbreitung der oozysten | |
IL90134A0 (en) | Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions | |
FI113621B (fi) | Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi | |
CA2102624A1 (en) | Transmission-blocking vaccine against malaria | |
DK0563254T3 (da) | Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner | |
ATE136933T1 (de) | Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe | |
ATE211923T1 (de) | Parenterale immunisierung gegen rotavirus | |
DE3851310T2 (de) | Synthetische Peptide, die immunologische Aktivität zeigen, benutzbar, um eine Impfung gegen Malaria vorzubereiten. | |
Liew | New Strategy for Control Forum: Vaccination | |
DE216901T1 (de) | Immunogenes antigen-traeger-proteinkonjugat zur verwendung in impfstoffen gegen malaria. | |
CA2156416A1 (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
TH3773A (th) | วัคซีนป้องกันมาเลเรีย |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |